Focal Segmental Glomerulosclerosis - Pipeline Insight, 2023

DelveInsight's , "Focal Segmental Glomerulosclerosis - Pipeline Insight, 2023," report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Focal Segmental Glomerulosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Focal Segmental Glomerulosclerosis Understanding

Focal Segmental Glomerulosclerosis: Overview

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease characterized by dysfunction in the part of the kidney that filters blood (the glomeruli). FSGS, can be caused by a variety of conditions including diabetes, sickle cell disease, other kidney diseases, obesity, an infection, drug toxicity or by inherited abnormal genes. FSGS can be mainly divided into Primary FSGS, secondary FSGS, and Genetic FSGS. Diagnosis of FSGS is based on blood test, urine test, and/or a kidney biopsy. Detailed medical history, patient examination and laboratory tests are essential to distinguish between primary (idiopathic) and secondary forms of FSGS. The standard first-line treatment for FSGS is prednisone. The short-term goal of treatment is to stop protein spillage completely and the long-term goals of treatment include preventing relapses of protein in the urine and preventing the deterioration of kidney function.

"Focal Segmental Glomerulosclerosis - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Focal Segmental Glomerulosclerosis pipeline landscape is provided which includes the disease overview and Focal Segmental Glomerulosclerosis treatment guidelines. The assessment part of the report embraces, in depth Focal Segmental Glomerulosclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Focal Segmental Glomerulosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

The companies and academics are working to assess challenges and seek opportunities that could influence Focal Segmental Glomerulosclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Focal Segmental Glomerulosclerosis.

Focal Segmental Glomerulosclerosis Emerging Drugs Chapters

This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Focal Segmental Glomerulosclerosis Emerging Drugs

Sparsentan: Travere Therapeutics

Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate selectively targeting the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, reduces proteinuria, protects podocytes and prevents glomerulosclerosis and mesangial cell proliferation. Sparsentan has been granted Orphan Drug Designation for the treatment of FSGS and IgAN in the US and Europe. Sparsentan is currently being evaluated in the pivotal Phase III. DUPLEX Study for the treatment of FSGS. The goal of the sparsentan program for FSGS is to develop a well-tolerated, safe and effective treatment that sustainably reduces proteinuria and protects the long-term health of kidneys in people living with FSGS.

DMX-200: Dimerix Bioscience

DMX-200 is a chemokine receptor (CCR2) blocker and is administered to patients taking an angiotensin II type I (AT1) receptor blocker (ARB), which the standard of care treatment for kidney disease. DMX-200 has granted patents in various territories until 2032. In 2020, DMX-200 demonstrated clear benefit to patients with FSGS in its first Phase IIa study in patients specifically with FSGS, following several successful studies in patients with a range of Chronic Kidney Diseases. All trial endpoints were achieved, and DMX-200 was determined to be safe and tolerable. DMX-200 for FSGS is currently in a Phase III clinical trial and has been granted Orphan Drug Designation by the FDA and EMA.

PF-06730512: Pfizer

PF-06730512 is a first-in-class, recombinant, ROBO2 human immunoglobulin G1 (IgG1) crystallized fragment (Fc) fusion protein in clinical development for the treatment of FSGS. By acting as a neutralizing ligand trap through preventing the interaction of SLIT2 with ROBO2, PF-06730512 may reduce downstream ROBO2/SLIT2 signaling and improve podocyte structure and function. It is currently being investigated in Phase II stage of development for the treatment of focal segmental glomerulosclerosis.

BI764198: Boehringer Ingelheim

BI 764198 is an oral TRPC6 (transient receptor potential cation channel subfamily C6) inhibitor being developed by Boehringer Ingelheim, for the treatment of Focal Segmental Glomerulosclerosis in Phase II clinical trial.

Further product details are provided in the report……..

Focal Segmental Glomerulosclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Focal Segmental Glomerulosclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Focal Segmental Glomerulosclerosis

There are approx. 20+ key companies which are developing the therapies for Focal Segmental Glomerulosclerosis. The companies which have their Focal Segmental Glomerulosclerosis drug candidates in the most advanced stage, i.e. Phase III include, Travere Therapeutics.

Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Focal Segmental Glomerulosclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Focal Segmental Glomerulosclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Focal Segmental Glomerulosclerosis drugs.

Focal Segmental Glomerulosclerosis Report Insights

• Focal Segmental Glomerulosclerosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Focal Segmental Glomerulosclerosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Focal Segmental Glomerulosclerosis drugs?
• How many Focal Segmental Glomerulosclerosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Focal Segmental Glomerulosclerosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Focal Segmental Glomerulosclerosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Focal Segmental Glomerulosclerosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Travere Therapeutics
• ZyVersa Therapeutics
• Dimerix Bioscience
• Chinook Therapeutics
• Goldfinch Bio
• Delta 4
• Angion Biomedica
• Surrozen
• Vertex Pharmaceuticals
• Pfizer
• Kyowa Kirin
• Boehringer Ingelheim
• ValenzaBio, Inc.
• River 3 Renal Corp.
• Certa Therapeutics
• Evergreen Therapeutics
• Ceptur Therapeutics
• Horizon Therapeutics
• Aurinia Pharmaceuticals
• Imara Inc.

Key Products

• Sparsentan
• VAR 200-01
• DMX-200
• Atrasentan
• GFB 887
• Research programme: focal segmental glomerulosclerosis therapeutics
• ANG-3070
• Research programme: regenerative therapeutics
• VX-147
• PF-06730512
• Bleselumab
• R3R01
• PF-06730512
• VB119
• BI 764198
• OCX-063
• D4-101-02
• EG-102
• Research programme: oligonucleotides
• VAR 200
• Dazodalibep
• IMR-261